Article

Blind De Novo Design of Dual Cyclic Peptide Agonists Targeting GCGR and GLP1R

2025-06-08

Abstract excerpt

Agonists of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP1R) are key to treating metabolic diseases like type 2 diabetes and obesity, but often limited by being linear. Cyclic peptides offer greater stability and potential oral delivery, but their de novo design with computational methods as agonists is unproven. Here, we used the EvoBind AI platform to design cyclic peptide agonists for G...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cc1cac17-92ed-5420-a905-55386852a4c1
DOI: 10.1101/2025.06.06.658268

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Blind De Novo Design of Dual Cyclic Peptide Agonists Targeting GCGR and GLP1RDOI 10.1101/2025.06.06.658268Read

Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesitySemantic proximity Read

De novo designed cyclic MC4R peptide agonist reduces food intake in miceSemantic proximity Read

Tuning Insulin Receptor Signaling Using <i>De Novo</i> Designed AgonistsSemantic proximity Read

Structural Biophysics-Guided Computational Design of Semaglutide Analogues to Enhance GLP-1R ActivationSemantic proximity Read

Structural basis for the identification of short novel peptides as potential GLP1R agonists using in silico approachesSemantic proximity Read

A conserved and druggable pocket in class B G protein coupled receptors for orally active small molecule agonistsSemantic proximity Read

Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeuticsSemantic proximity Read

Structural Biophysics-Guided Computational Design of Semaglutide Analogues to Enhance GLP-1R ActivationSemantic proximity Read

DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.Semantic proximity Read

The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicinesSemantic proximity Read

Generation of High-Affinity Anti-GIPR Antagonist Antibodies with Sustained and Non-rebound Weight Loss in DIO Mice by AlfaBodYSemantic proximity Read

Structural dynamics underlying agonist activation of a GLP-1R-Gs precoupled complexSemantic proximity Read